News

TiGenix provides regulatory update on Cx601 EU Marketing Authorization Application procedure

Leuven (BELGIUM) – May 31, 2017, 07:00h CEST – TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic, or donor-derived, stem cells to develop novel therapies for serious medical conditions, today announces that it will submit responses to the Cx601 Marketing Authorization Application Day 180 List of Outstanding Issues (LoOI) during the month of August.

2017-06-20T12:14:43+00:00